Skip to main content

Landos Biopharma, Inc.

LABPDelisted May 23, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001785345

Landos Biopharma, Inc. was delisted on May 23, 2024; its insiders filed their last Form 4 on May 23, 2024; 16 institutions reported holding it in 13F filings for Q1 2024, worth $34.9M in total; no superinvestor held it.

Q3 2022 vs. Q2 2022

How the institutions holding Landos Biopharma, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of LABP: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders3531−4
Shares22.5M21.6M−861.2K (−3.8%)
Value$16.4M$14.0M−$2.31M (−14.1%)

New holders (5)

Institutions that held Landos Biopharma, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to LABP in Q3 2022
InstitutionSharesValue% of portfolio
Green Square Capital Advisors LLC84,500$55.0K0.01%
Balyasny Asset Management LLC15,687$10.0K0.00%
Man Group plc14,387$9.00K0.00%
BNP Paribas Arbitrage, SA1,122$7290.00%
China Universal Asset Management Co., Ltd.377$00.00%

Sold out (9)

Institutions that held Landos Biopharma, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of LABP in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Ergoteles LLC22,900$17.0K
Citadel Advisors LLC21,119$16.0K
Jane Street Group, LLC20,957$15.0K
Susquehanna International Group, LLP12,529$9.00K
Raymond James & Associates10,350$8.00K
Allworth Financial LP5,286$4.00K
UBS Group AG1,243$1.00K
Credit Suisse AG3$0
Advisor Group Holdings, Inc.418$0